Kondo, Shunsuke

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Llovet, J. M., Kudo, M., Merle, P., Meyer, T., Qin, S., Ikeda, M., Xu, R., Edeline, J., Ryoo, B.-Y., Ren, Z., et al. (2023) · The Lancet Oncology

Hepatocellular Carcinoma Treatment and PrognosisColorectal Cancer Treatments and Studies

Cited by 469

Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer

Hayashi, H., Kohno, T., Ueno, H., Hiraoka, N., Kondo, S., Saito, M., Shimada, Y., Ichikawa, H., Kato, M., Shibata, T., et al. (2017) · Pancreas

Pancreatic and Hepatic Oncology ResearchCancer Genomics and Diagnostics

Cited by 88

Phase 1b study of galunisertib in combination with gemcitabine in Japanese patients with metastatic or locally advanced pancreatic cancer

Ikeda, M., Takahashi, H., Kondo, S., Lahn, M. M. F., Ogasawara, K., Benhadji, K. A., Fujii, H., & Ueno, H. (2017) · Cancer Chemotherapy and Pharmacology

Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and Treatment

Cited by 51

1622P D-1553 in patients with KRAS G12C mutated advanced pancreatic cancer (pca)

Kondo, S., Yan, D., Ganju, V., Richardson, G., Hou, X., Shan, J., Liu, X., Zhang, Y., Xie, X., Xiang, Z., et al. (2023) · Annals of Oncology

Pancreatic and Hepatic Oncology ResearchProtein Kinase Regulation and GTPase Signaling

Cited by 6